ST
NKTR icon

Smithfield Trust’s Nektar Therapeutics NKTR Stock Holding History

Smithfield Trust’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15
Closed -$4K – 1088
2021
Q3 		$4K Hold
15
– – ﹤0.01% 1037
2021
Q2 		$4K Hold
15
– – ﹤0.01% 1005
2021
Q1 		$4K Hold
15
– – ﹤0.01% 1030
2020
Q4 		$4K Hold
15
– – ﹤0.01% 1009
2020
Q3 		$4K Buy
15
+8
+114% +$2.52K ﹤0.01% 971
2020
Q2 		$2K Buy
+7
New +$2.18K ﹤0.01% 981
2020
Q1 		– Sell
-8
Closed -$3K – 994
2019
Q4 		$3K Sell
8
-7
-47% -$2.03K ﹤0.01% 878
2019
Q3 		$4K Buy
15
+7
+88% +$2.57K ﹤0.01% 871
2019
Q2 		$4K Hold
8
– – ﹤0.01% 850
2019
Q1 		$4K Hold
8
– – ﹤0.01% 802
2018
Q4 		$4K Hold
8
– – ﹤0.01% 777
2018
Q3 		$8K Hold
8
– – ﹤0.01% 762
2018
Q2 		$6K Hold
8
– – ﹤0.01% 803
2018
Q1 		$13K Hold
8
– – ﹤0.01% 681
2017
Q4 		$7K Buy
+8
New +$4.73K ﹤0.01% 803

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Smithfield Trust's NKTR Position: Q4 2021 in Review

Smithfield Trust sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 15 shares — an estimated $4K sold.

Smithfield Trust first reported a position in NKTR in Q4 2017 and held it in 15 quarters. The position peaked at $13K in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

  • Smithfield Trust reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Smithfield Trust sold 15 Nektar Therapeutics shares in Q4 2021, an estimated $4K.
  • Smithfield Trust first reported a position in Nektar Therapeutics in Q4 2017 and held it in 15 quarters.
  • Smithfield Trust's Nektar Therapeutics position peaked at $13K in Q1 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Smithfield Trust's 13F filing for Q4 2021, filed 14 Feb 2022.